Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer
Background According to previous literatures, plasma thioredoxin reductase (TrxR) level was significantly elevated in various malignant tumors and serve as a potential biomarker for diagnosis and prognostic prediction. However, there is little awareness of the clinical value of plasma TrxR in gyneco...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-06-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338231184995 |
| _version_ | 1797794410030694400 |
|---|---|
| author | Yinxing Zhu MS Yixuan Hu MS Junfeng Shi MD Xiaowei Wei MD Yaqi Song MD Cuiju Tang MD, PhD Wenwen Zhang MD, PhD |
| author_facet | Yinxing Zhu MS Yixuan Hu MS Junfeng Shi MD Xiaowei Wei MD Yaqi Song MD Cuiju Tang MD, PhD Wenwen Zhang MD, PhD |
| author_sort | Yinxing Zhu MS |
| collection | DOAJ |
| description | Background According to previous literatures, plasma thioredoxin reductase (TrxR) level was significantly elevated in various malignant tumors and serve as a potential biomarker for diagnosis and prognostic prediction. However, there is little awareness of the clinical value of plasma TrxR in gynecologic malignancies. In the present study, we aim to evaluate the diagnostic accuracy of plasma TrxR in gynecologic cancer and explore its role in treatment surveillance. Methods We retrospectively enrolled 134 patients with gynecologic cancer and 79 patients with benign gynecologic disease. The difference of plasma TrxR activity and tumor markers level between two groups was compared using Mann-Whitney U test. By detecting pretreatment and post-treatment level of TrxR and conventional tumor markers, we further assessed the change trend of them with the Wilcoxon signed-ranks test. Results Compared with benign control [5.7 (5, 6.6) U/mL], statistically significant increase of TrxR activity was observed in gynecologic cancer group [8.4 (7.25, 9.825) U/mL] ( P < .0001), regardless of age and stage. On the basis of receiver operating characteristic (ROC) curves, we found plasma TrxR shows the highest diagnostic efficacy for distinguishing malignancy with benign disease, with an area under the curve (AUC) of 0.823 (95% confidence interval [CI] = 0.767-0.878), in the whole cohort. Besides, patients receiving treatment previously [8 (6.5, 9) U/mL] had a decreased TrxR level relative to treatment-native patients [9.9 (8.6, 10.85) U/mL]. Furthermore, follow-up data showed that plasma TrxR level would be evidently decreased after two courses of antitumor therapy ( P < .0001), which is consistent with the downward trend of conventional tumor markers. Conclusion Collectively, all these results demonstrated plasma TrxR is an effective parameter for gynecologic cancer diagnosis and concurrently acts as a promising biomarker for treatment response assessment. |
| first_indexed | 2024-03-13T03:02:22Z |
| format | Article |
| id | doaj.art-261d2da7756e4f4b906f6aceaf75e45a |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-03-13T03:02:22Z |
| publishDate | 2023-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-261d2da7756e4f4b906f6aceaf75e45a2023-06-27T11:04:09ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382023-06-012210.1177/15330338231184995Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic CancerYinxing Zhu MS0Yixuan Hu MS1Junfeng Shi MD2Xiaowei Wei MD3Yaqi Song MD4Cuiju Tang MD, PhD5Wenwen Zhang MD, PhD6 Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China Department of Oncology, , Nanjing Medical University, Nanjing, China Department of Oncology, , Nanjing Medical University, Nanjing, China Department of Oncology, , Nanjing Medical University, Nanjing, China Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China Department of Oncology, , Nanjing Medical University, Nanjing, China Department of Oncology, , Nanjing Medical University, Nanjing, ChinaBackground According to previous literatures, plasma thioredoxin reductase (TrxR) level was significantly elevated in various malignant tumors and serve as a potential biomarker for diagnosis and prognostic prediction. However, there is little awareness of the clinical value of plasma TrxR in gynecologic malignancies. In the present study, we aim to evaluate the diagnostic accuracy of plasma TrxR in gynecologic cancer and explore its role in treatment surveillance. Methods We retrospectively enrolled 134 patients with gynecologic cancer and 79 patients with benign gynecologic disease. The difference of plasma TrxR activity and tumor markers level between two groups was compared using Mann-Whitney U test. By detecting pretreatment and post-treatment level of TrxR and conventional tumor markers, we further assessed the change trend of them with the Wilcoxon signed-ranks test. Results Compared with benign control [5.7 (5, 6.6) U/mL], statistically significant increase of TrxR activity was observed in gynecologic cancer group [8.4 (7.25, 9.825) U/mL] ( P < .0001), regardless of age and stage. On the basis of receiver operating characteristic (ROC) curves, we found plasma TrxR shows the highest diagnostic efficacy for distinguishing malignancy with benign disease, with an area under the curve (AUC) of 0.823 (95% confidence interval [CI] = 0.767-0.878), in the whole cohort. Besides, patients receiving treatment previously [8 (6.5, 9) U/mL] had a decreased TrxR level relative to treatment-native patients [9.9 (8.6, 10.85) U/mL]. Furthermore, follow-up data showed that plasma TrxR level would be evidently decreased after two courses of antitumor therapy ( P < .0001), which is consistent with the downward trend of conventional tumor markers. Conclusion Collectively, all these results demonstrated plasma TrxR is an effective parameter for gynecologic cancer diagnosis and concurrently acts as a promising biomarker for treatment response assessment.https://doi.org/10.1177/15330338231184995 |
| spellingShingle | Yinxing Zhu MS Yixuan Hu MS Junfeng Shi MD Xiaowei Wei MD Yaqi Song MD Cuiju Tang MD, PhD Wenwen Zhang MD, PhD Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer Technology in Cancer Research & Treatment |
| title | Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer |
| title_full | Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer |
| title_fullStr | Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer |
| title_full_unstemmed | Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer |
| title_short | Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer |
| title_sort | plasma thioredoxin reductase as a potential biomarker for gynecologic cancer |
| url | https://doi.org/10.1177/15330338231184995 |
| work_keys_str_mv | AT yinxingzhums plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT yixuanhums plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT junfengshimd plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT xiaoweiweimd plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT yaqisongmd plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT cuijutangmdphd plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer AT wenwenzhangmdphd plasmathioredoxinreductaseasapotentialbiomarkerforgynecologiccancer |